Special Issue

Roles of Extracellular Vesicles in the Complex Interaction Between Metabolic Disorder and Cancer

Message from the Guest Editor

Metabolic disorders, such as obesity, diabetes, and cardiovascular diseases, have been linked to the development and progression of tumors.

Epidemiological studies have shown a strong correlation between metabolic abnormalities and the incidence of various types of cancer.

Extracellular vesicles (EVs), small membrane-bound vesicles released by cells, play a pivotal role in the intricate interplay between metabolic disorders and cancer. They serve as crucial vehicles for intercellular communication, carrying and transferring bioactive molecules such as proteins, lipids, metabolites, RNA, and DNA to recipient cells, thereby influencing their functions. They exacerbate metabolic disorders by conveying related signals and promote cancer growth and metastasis by delivering tumor-associated signals. EVs also serve as biomarkers and potential therapeutic carriers, offering new avenues for the prevention and treatment of these diseases. This Special Issue aims at understanding the mechanistic and therapeutic aspects of this crucial relationship in order to improve the prevention, diagnosis, and treatment of cancer.

Guest Editor

Dr. Keyang Xu

Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/231825

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).